PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and ...

​Zoetis Inc. (NYSE:ZTS) is one of the Good Stocks to Buy According to Analysts. On December 2, Zoetis Inc. (NYSE:ZTS) held its innovation day, highlighting its long-term growth opportunities. In addition, Wall Street maintains a positive outlook on the stock. ​Management noted that the animal health market is anticipated to grow nearly double the current size to $90 billion by 2035. This is pertinent for the company as its pipeline includes 12 candidates with blockbuster potential treating chronic kidney ...

Core Viewpoint - The article discusses the current stock market outlook and highlights 11 best and cheap stocks to buy, emphasizing the importance of earnings and interest rates in driving stock prices [2][4][8]. Market Outlook - Jeremy Siegel, a Wharton professor, believes the upward trend in the stock market will continue despite concerns about a government shutdown, as long as it does not last longer than two weeks [2]. - Siegel anticipates that the impact of tariffs will be more evident in the fourth quarter, particularly during the holiday retail season, and expects the Federal Reserve to cut interest rates by 0.25% in October and December [3][4]. Company Insights - **Sanofi (NASDAQ:SNY)**: - Forward P/E Ratio: 9.91, with 24 hedge fund holders [9]. - Recently announced a $625 million investment in Sanofi Ventures, increasing total assets to over $1.4 billion, focusing on biotech and digital health startups [10][11]. - Sanofi is a global healthcare company involved in researching, developing, and marketing medicines and vaccines [12]. - **Altria Group, Inc. (NYSE:MO)**: - Forward P/E Ratio: 12.07, with 54 hedge fund holders [13]. - Received a Buy rating from Bank of America Securities with a price target of $72, highlighting its partnership with KT&G Corp to enhance growth in the oral nicotine market [14][15]. - Altria is a leading American tobacco company providing a range of tobacco products for adult consumers [15].

Core Insights - Zoetis Inc. has secured a new five-year $1.25 billion senior unsecured revolving credit facility, enhancing its financial flexibility [2][3] - The new credit facility replaces a previous agreement from 2022 and is administered by JPMorgan Chase, with other major banks acting as syndication agents [2] - The facility allows Zoetis to borrow against base or SOFR rates with a margin linked to its debt ratings, providing liquidity for operations and strategic initiatives [3] Financial Flexibility - The new credit facility has no mandatory prepayments and offers flexible repayment terms, which is advantageous for the company's financial management [3] - This move is expected to support Zoetis's operations and strategic initiatives, indicating a proactive approach to maintaining liquidity [3] Company Overview - Zoetis Inc. specializes in preparing medicines, vaccines, diagnostics, and precision health solutions for both livestock and companion animals globally [3] - The company is recognized as one of the best stocks for Roth IRA investments, highlighting its potential as a stable investment option [1][3]

Core Insights - President Trump's tariffs are contributing to significant investments in U.S. manufacturing by major corporations, including semiconductor and pharmaceutical companies [1][3][5] Semiconductor Industry - Taiwan Semiconductor Manufacturing (TSMC) announced a $100 billion investment in U.S. facilities [1] - NVIDIA plans to produce $500 billion worth of AI infrastructure in the U.S. over the next four years [2] Pharmaceutical Industry - Three major pharmaceutical companies are set to invest over $100 billion in the U.S. in the coming years [3] - Roche plans to invest $50 billion in the U.S. over the next five years, expecting to create 12,000 new jobs and export more medicines than it imports [5][6] - Novartis announced a $23 billion investment over the next five years, aiming to produce 100% of its core drugs in the U.S. and create 4,000 jobs [8][10] - Johnson & Johnson is investing more than $55 billion in the U.S. over the next four years, a 25% increase from the previous period, and plans to build three new manufacturing plants [13][14]